Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$6.04 USD
+0.17 (2.90%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $6.04 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Aldeyra Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 143 | 174 | 230 | 78 | 73 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 3 | 5 | 2 |
Total Current Assets | 148 | 181 | 233 | 83 | 75 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 148 | 181 | 233 | 83 | 76 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 1 | 0 | 1 |
Current Portion Long-Term Debt | 15 | 1 | 0 | 4 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 14 | 11 | 8 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 15 | 12 | 12 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 15 | 16 | 11 | 15 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 30 | 27 | 24 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 514 | 508 | 500 | 296 | 247 |
Retained Earnings | -394 | -357 | -295 | -237 | -199 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 120 | 151 | 206 | 60 | 48 |
Total Liabilities & Shareholder's Equity | 148 | 181 | 233 | 83 | 76 |
Total Common Equity | 120 | 151 | 206 | 60 | 48 |
Shares Outstanding | 58.80 | 58.50 | 58.00 | 38.80 | 27.90 |
Book Value Per Share | 2.04 | 2.58 | 3.55 | 1.53 | 1.72 |
Fiscal Year End for Aldeyra Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 120 | 133 | 143 | 143 | 152 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 8 | 5 | 4 | 4 |
Total Current Assets | 126 | 141 | 148 | 147 | 155 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 126 | 141 | 148 | 147 | 156 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 1 | 0 | 0 |
Current Portion Long-Term Debt | 15 | 15 | 15 | 13 | 6 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 6 | 6 | 8 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 28 | 22 | 22 | 22 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 6 | 6 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 3 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 28 | 29 | 24 | 26 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 517 | 516 | 514 | 512 | 511 |
Retained Earnings | -419 | -402 | -394 | -390 | -381 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 98 | 113 | 120 | 123 | 130 |
Total Liabilities & Shareholder's Equity | 126 | 141 | 148 | 147 | 156 |
Total Common Equity | 98 | 113 | 120 | 123 | 130 |
Shares Outstanding | 59.40 | 59.40 | 58.80 | 58.60 | 58.50 |
Book Value Per Share | 1.66 | 1.91 | 2.04 | 2.10 | 2.22 |